AI-assisted, human-published
09/09/2024 /Funding Events
Epsilogen Secures £12.5M Series B Financing for Cancer Treatment Development
Epsilogen finalizes £12.5 million Series B expansion financing, bringing the total to £43.25 million, to support clinical Proof of Concept for MOv18 IgE in a phase Ib trial for platinum-resistant ovarian cancer and advance IgE-based pipeline.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com